Navigation Links
Relmada Therapeutics Announces LevoCap ER Development Progress
Date:3/4/2013

BLUE BELL, Pa., March 4, 2013 /PRNewswire/ -- Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the approval of the application of a Clinical Trial Authorization (CTA) that was submitted with the Medicine and Health Regulatory Agency (MHRA) to conduct a Phase I pharmacokinetic study with the development product abuse-deterrent LevoCap extended release (ER) capsules.  The MHRA is the UK government agency which is responsible for ensuring that medicines and medical devices work and are acceptably safe.

This Phase I safety study is designed to assess the bioavailability and dose proportionality of three levorphanol extended release (ER) formulations, how these compare with a marketed IR (immediate release) product available in the US, and whether there are any differences under fed and fasted conditions.

"This significant progress is in line with the development plan of LevoCap ER. If this study shows positive results, then we will be on track to enter the phase III program in the fourth quarter," said Sergio Traversa , CEO of Relmada.

LevoCap ER, Relmada's lead product is intended to add a powerful new tool to treat pain where opioids alone or non-opioids alone do not provide adequate relief.  Unlike other opioids, levorphanol, the active ingredient in LevoCap ER modulates pain through both opioid pathways and noradrenergic pathways thereby providing pain relief through multiple mechanisms in one capsule. Levorphanol has also been shown to partially reverse analgesic tolerance to morphine and may therefore benefit patients who are tolerant to the analgesic effects of their current opioid. 

Based on its pharmacological profile, LevoCap alone should demonstrate improved efficacy in a broader patient population compared to other opioids.  This includes the vast category of patients affected by chronic pain with combined nociceptive and neuropathic components, which frequently require treatment with two or more pain medications to achieve efficacy. 

About Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical stage, private biopharmaceutical company focused on developing both novel versions of proven drugs and new molecules that potentially address high unmet medical needs in the treatment of chronic pain.  The Company has a deep and diversified portfolio of four lead products at different stages of development and an early stage pipeline of an additional three products. 

For more information, contact:

Visit our website at www.relmada.com



'/>"/>
SOURCE Relmada Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential
2. Autoinjectors to 2018 - Devices, Therapeutics, Markets, Strategies and Prospects
3. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
4. ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"
5. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
6. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
7. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
8. Frost & Sullivan Recognizes KAERs Game-Changing Innovating Aerosol Drug Delivery Methods for High-Dose Respiratory Disease Therapeutics
9. United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
10. iBio And Caliber Biotherapeutics Establish License And Collaboration Relationship
11. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):